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Abstract
Background: Several studies showed Type 2 Diabetes Mellitus (T2DM) to be associated with worse adverse clinical
outcomes compared to non-T2DM (NDM) following Percutaneous Coronary Intervention (PCI). In addition, patients
with insulin-treated T2DM (ITDM) showed worse clinical outcomes compared to patients with non-insulin treated
T2DM (NITDM). Since NITDM and NDM have seldom been systematically analyzed, this study aimed to compare
the short and long term adverse clinical outcomes observed in patients with NITDM and patients without T2DM
following PCI.
Methods: Medline/PubMed, EMBASE and the Cochrane library were searched for Randomized Controlled Trials
(RCTs) and observational studies comparing patients with (including ITDM and NITDM) and without T2DM
following PCI. Endpoints included adverse clinical outcomes reported during a short and a long term follow up
period. Odd Ratios (OR) and 95% Confidence Intervals (CI) in accordance with either a fixed or a random effects
model appropriately, were calculated and the pooled analyses were performed with RevMan 5.3.
Results: Twelve studies consisting of a total number of 52,451 patients (14,863 NITDM and 37,588 NDM) were
included. Patients with NITDM were found to have significantly higher short-term Major Adverse Cardiac Events
(MACEs) and mortality with OR: 1.63, 95% CI (1.17, 2.27); P = 0.004 and OR: 1.71, 95% CI (1.40, 2.10), P < 0.00001
respectively and higher long-term MACEs and mortality with OR: 1.25, 95% CI (1.12, 1.40), P = 0.0001 and OR: 1.32,
95% CI (1.19, 1.47), P < 0.00001 respectively compared to NDM following PCI. In addition, compared to NDM,
long-term Target Vessel Revascularization (TVR) and Target Lesion Revascularization (TLR) were significantly
higher in the NITDM group with OR: 1.36, 95% CI (1.18, 1.56), P < 0.0001 and OR: 1.32, 95% CI (1.10, 1.59), P = 0.003
respectively. However, even if an increased long-term stent thrombosis was observed in the NITDM group with
OR: 1.13; 95% CI (0.91, 1.40), P = 0.28, the result was insignificant.
Conclusion: Short and long term MACEs and mortality were significantly higher in patients with NITDM compared
to patients without diabetes following PCI. Revascularization also significantly favored patients without T2DM.
However, stent thrombosis was not significantly different.
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Background
Patients with Type 2 Diabetes Mellitus (T2DM) have
worse clinical outcomes compared to patients without
T2DM (NDM) following Percutaneous Coronary Inter-
vention (PCI). For example, the PRESTO trial showed that
despite advances in interventional techniques, diabetes
mellitus remained a significant predictor of adverse clin-
ical events after PCI [1, 2]. Later on, it was shown that pa-
tients with insulin-treated T2DM (ITDM) had even worse
adverse outcomes compared to patients with non-insulin
treated T2DM (NITDM). To further illustrate this point,
the FREEDOM trial showed a significantly higher rate of
Major Adverse Cardiac Effects (MACEs) in those diabetic
patients who were on insulin therapy following PCI com-
pared to those patients without insulin therapy [2]. It is
clear that patients without T2DM when compared to pa-
tients with T2DM and patients with NITDM compared to
ITDM have lower adverse clinical events following PCI.
Since NITDM and NDM have seldom been systematically
analyzed, this study aimed to compare the short and long
term adverse clinical outcomes observed in patients with
NITDM and patients without T2DM following PCI.
Methods
Data sources and search strategy
Studies including Randomized Controlled Trials (RCTs)
and observational studies were searched from Medline/
PubMed, EMBASE and the Cochrane databases using
the words ‘diabetes mellitus and percutaneous coronary
intervention/PCI’ or ‘insulin-treated and non-insulin
treated diabetes mellitus and PCI’. The term ‘angioplasty’
and the abbreviations ‘T2DM and DM’ were also used.
Reference lists of relevant publications obtained were
also checked for suitable articles. Our search began on
2nd May 2015 and ended on 30th September 2015. This
search was restricted only to articles which were pub-
lished in English language.
Inclusion and exclusion criteria
Studies were included if:
(a)They were randomized trials and observational
studies comparing the adverse outcomes between
T2DM (including ITDM and NITDM) and NDM
following PCI.
(b)They were published during or after the year 2006
(from the year 2006 to 2015).
Studies were excluded if:
(a)Data concerning patients with NITDM could not be
retrieved from these diabetic patients.
(b)Patients without T2DM were not included as
the control.
(c)Adverse clinical outcomes were not reported among
their endpoints.
(d)They were meta-analyses, case studies or letter
to editors.
(e)They were published before the year 2006.
(f ) They were duplicates.
Definitions, outcomes and follow up periods
NITDM were defined as patients who were at an earlier
stage of T2DM, or did not have any diabetic complications
or patients with a good control of their blood glucose
levels, therefore not requiring insulin therapy as treat-
ment. These patients were either on a diet control or on
oral hypoglycemic agents.
The adverse clinical outcomes were:
(a)Mortality: defined as all-cause mortality including
cardiac and non-cardiac deaths.
(b)MACEs: were defined as death of cardiac or
procedure-related origin, myocardial infarction,
and/or, revascularization following coronary stents
implantation. Due to limited outcomes reported,
major adverse cardiac and cerebrovascular events
(MACCEs) were considered in the same category
as MACEs and analyzed in this study.
(c)Target lesion revascularization (TLR) and Target
vessel revascularization (TVR)
(d)Myocardial infarction (MI): was defined as
re-infarction which occurred in these patients
after PCI. Any type of MI was relevant.
(e)Stent thrombosis (ST): Any type of ST was
considered acceptable during this analysis.
Short term follow-up period: was defined as a follow-
up period of less than 1 year.
Long term follow-up period: was defined as a follow
up at or during one or more years (≥ one year).
Data extraction and quality assessment
Eligible studies were independently assessed by NL,
YJY and MHC. The types of study and patients’ base-
line characteristics, the total number of patients with
NITDM and without T2DM respectively, the year of
publication, the clinical outcomes (MACEs, death, ST,
TVR, TLR, MI) and the follow up duration were sys-
tematically extracted. Any disagreement which followed
was resolved by consensus. Cochrane Collaboration
was considered during bias risk assessment [3].
Methodological quality and statistical analysis
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement was followed in this type
of research article [4]. The Cochrane Q-statistic test
(p value ≤ 0 · 05 was considered statistically significant)
Li et al. BMC Cardiovascular Disorders  (2016) 16:238 Page 2 of 11
and the I2-statistic test (I2 value of 0% indicated a very
low heterogeneity) were used to assess heterogeneity. An
I2 value less than 50% indicated the use of a fixed effects
model, whereas a random effects model was used if I2
was greater than 50%. Funnel plots were used to assess
publication bias.
We calculated Odd Ratios (OR) with 95% Confidence
Intervals (CIs). The pooled analyses were performed
with RevMan 5.3 software. All the authors had access to
the data which were used in this study. Ethical approval
was not necessary for this meta-analysis.
Results
Study selection
Two thousand four hundred and thirty-two articles were
identified by titles and abstracts obtained from Medline/
PubMed, EMBASE and the Cochrane library. An add-
itional 16 articles were identified from the reference
lists of suitable articles. After eliminating the duplicate
studies, further articles were excluded since they were
not relevant to the topic of this research. Forty-four
full-text articles were assessed for eligibility. Another
32 articles were excluded for the following reasons: data
for patients with NITDM could not be retrieved, data
were not usable or the studies were published before
the year 2006. Finally, 12 articles [5–16] were selected
for this meta-analysis. The flow chart showing study se-
lection has been illustrated in Fig. 1.
Table 1 shows the clinical outcomes reported in each
of the 12 studies included.
General features of the studies included in this analysis
Table 2 represents the general features including the
total number of patients in the NITDM and the NDM
groups respectively, the type of study, and the follow-up
periods of each of the studies included in this analysis.
As shown in Table 2, this meta-analysis included a total
number of 52,451 patients among which, 14,863 were
NITDM patients, whereas 37,588 patients were NDM.
Baseline characteristics
Data reporting the mean age of the patients in years,
the percentage of patients with male gender, with co-
morbidities such as hypertension, dyslipidemia and the
percentage of patients who were current smokers were
listed in Table 3. According to Table 3, no significant
Fig. 1 Flow diagram representing the study selection
Li et al. BMC Cardiovascular Disorders  (2016) 16:238 Page 3 of 11
differences were observed in the baseline characteristics
between these two groups of patients (NITDM and NDM).
Results of this meta-analysis
A total number of 4163 patients were analyzed for
MACEs and MI respectively and 17,015 patients were
analyzed for mortality during the short-term follow-up
period.
This analysis showed a significantly higher rate of
MACEs and MI in the NITDM group with OR: 1.63, 95%
CI (1.17, 2.27); P = 0.04 and OR: 1.82, 95% CI (1.08, 3.06);
P = 0.02 when compared to NDM respectively during the
short term follow up period following PCI. Compared
to NDM, the mortality rate was also significantly higher
in the NITDM group with OR: 1.71, 95% CI (1.40, 2.10),
P < 0.00001. Results representing the short-term outcomes
were illustrated in Fig. 2. Table 4 summarized the result
for the short-term follow up period.
For the long-term follow up period, a total number of
21,465 patients were analyzed for MACEs, 37,756 pa-
tients were analyzed for mortality, 31,964 patients were
analyzed for MI, 30,388 patients were analyzed for TLR,
14,320 patients were analyzed for TVR and 36,900 pa-
tients were analyzed for ST.
This current long-term analysis showed a significantly
higher MACEs and mortality in the NITDM group with
OR: 1.25, 95% CI (1.12, 1.40), P = 0.0001 and OR: 1.32,
95% CI (1.19, 1.47), P < 0.00001 respectively, and a sig-
nificantly higher rate of TLR and TVR with OR: 1.32,
95% CI (1.10, 1.59), P = 0.003 and OR: 1.36, 95% CI
(1.18, 1.56), P < 0.0001 respectively when compared to
NDM. MI was similarly manifested with OR: 1.03, 95%
CI (0.89, 1.21); P = 0.67. However, compared to NDM,
even if the long-term ST was higher in the NITDM
group, the result was not statistically significant with
OR: 1.13, 95% CI (0.91, 1.40), P = 0.28. Results for the
Table 1 Outcomes reported in each study
Study Reported Outcomes
Kappetein 2013 [5] MACCE, Death, MI, Revascularization, Stent thrombosis
Kereiakes 2010 [6] MACEs, MI, Stent thrombosis
Kirtane 2008 [7] Death, MI, TLR, TVR, Stent thrombosis
Kirtane 2009 [8] MACEs, Death, MI, TLR, TVR, Stent thrombosis
Kumar 2007 [9] MACEs, Death, MI, TLR, Stent thrombosis
Stone 2011 [10] MACEs, Death, MI, TLR, Stent thrombosis
Tada 2011 [11] Death, MI, TLR, Stent thrombosis
Thukkani 2015 [12] Death
Witzenbichler 2011 [13] MACEs, MI, Death, TVR, Stent thrombosis
Massalha 2015 [14] Death
Jain 2010 [15] MACEs, MI, TLR, TVR, Stent thrombosis
Silber 2013 [16] Death, MACEs, TLR, TVR, Stent thrombosis
Abbreviations: MACEs major adverse cardiac events, MI myocardial infarction, TVR target vessel revascularization, TLR target lesion revascularization
Table 2 General features of the included studies
Study No of NITDM No of NDM Type of study Follow up
Kappetein 2013 [5] 142 672 RCT 5 years
Kereiakes 2010 [6] 826 2467 RCT 1 year
Kirtane 2008 [7] 562 2686 RCT 4 years
Kirtane 2009 [8] 333 1071 RCT 1 year
Kumar 2007 [9] 182 541 OS 9 months
Stone 2011 [10] 1375 4911 RCT 2 years
Tada 2011 [11] 3404 6378 OS 3 years
Thukkani 2015 [12] 4862 7990 OS ≤12 months > 12
Witzenbichler 2011 [13] 434 3006 RCT 30 days, 1 year
Massalha 2015 [14] 196 694 OS 5 years
Jain 2010 [15] 1919 5269 OS 1 year
Silber 2013 [16] 628 1903 RCT 2 years
Abbreviations: NITDM non-insulin treated diabetes mellitus, NDM non-diabetes mellitus, RCT randomized controlled trials, OS observational studies
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long-term follow up period were illustrated in Figs. 3, 4
and 5. Table 5 summarized the results for this long-
term follow up period.
A separate analysis was conducted (excluding observa-
tional studies) involving only randomized trials. The re-
sults showed long term MACEs and TVR to be
significantly higher in the NITDM group with OR: 1.19,
95% CI (1.03, 1.36); P = 0.02 and OR: 1.47, 95% CI (1.23,
1.74); P < 0.0001 respectively when compared to NDM.
However, even if mortality was higher in the NITDM
group with OR: 1.20, 95% CI (0.96–1.50); P = 0.10, the
result was not statistically significant. These results have
been shown in Fig. 6. In addition, long term MI and ST
were also not significantly different between these 2
groups with OR: 1.04, 95% CI (0.85, 1.28); P = 0.68 and
OR: 1.05, 95% CI (0.77, 1.43); P = 0.75 respectively.
These results have been shown in Fig. 7.
For the included studies, publication bias was visual
estimated through funnel plots. Little evidence of publi-
cation bias was observed for the included studies that
assessed all clinical endpoints (Fig. 8a–c).
Discussion
Many studies have shown T2DM to be independently
associated with increased adverse clinical outcomes
following PCI compared to patients without T2DM.
Other studies have shown the adverse complications to
be significantly higher in patients with ITDM compared
Table 3 Baseline features of the included studies
Study Age (years) Males (%) HT (%) Ds (%) Cs (%)
NI/NDM NI/NDM NI/NDM NI/NDM NI/NDM
Kappetein 2013 [5] 65.4/65.0 71.0/79.9 70.0/65.0 82.0/77.0 16.0/22.0
Kereiakes 2010 [6] 63.3/63.4 63.3/70.0 87.0/71.9 82.5/72.6 18.3/24.0
Kirtane 2008 [7] 63.0/62.1 64.7/75.0 82.1/64.5 74.0/69.6 18.4/24.9
Kirtane 2009 [8] 64.0/63.3 60.4/71.0 90.6/76.7 87.1/81.4 54.1/64.8
Kumar 2007 [9] 67.0/66.0 67.0/73.0 93.0/77.0 92.0/80.0 8.0/14.0
Stone 2011 [10] 63.8/63.0 63.2/71.3 83.1/62.5 79.4/64.0 19.6/27.1
Tada 2011 [11] 67.9/68.8 76.0/76.0 78.0/73.0 − 21.0/20.0
Thukkani 2015 [12] 64.3/64.2 98.5/98.3 96.4/88.5 82.9/80.0 36.7/48.7
Witzenbichler 2011 [13] 64.5/59.6 73.4/77.2 72.3/49.8 60.3/39.7 56.8/64.9
Massalha 2015 [14] 63.0/58.0 71.0/84.0 65.0/41.0 − 22.0/23.0
Jain 2010 [15] 64.9/62.3 71.8/80.2 77.5/63.7 − 18.0/25.4
Silber 2013 [16] 65.5/63.5 70.4/74.4 86.0/73.1 86.0/76.0 18.6/22.1
Abbreviations: HT hypertension, Ds dyslipidemia, Cs current smoker, NI: non-insulin treated diabetics, NDM non-diabetics
Fig. 2 Short term adverse clinical outcomes observed between non-insulin treated T2DM and non-T2DM
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to patients with NITDM. We aimed to compare the
clinical outcomes between NITDM and NDM in order
to know whether they have similar outcomes or not fol-
lowing PCI.
Results of this analysis showed significantly higher
long and short term mortality and MACEs in the
NITDM group compared to the NDM group. MI was
similarly manifested whereas revascularization was sig-
nificantly higher in patients with T2DM. Moreover, even
if ST was higher in patients with NITDM compared to
patients without T2DM, the result was not statistically
significant in this current study.
Similar to this current analysis, the study published by
Kappetein et al. also showed significantly higher MACEs
and repeated revascularization (TLR and TVR) in pa-
tients with NITDM compared to those without T2DM
following PCI [5]. Moreover, the PRESTO Trial which
included 75% of patients with T2DM not on insulin
therapy, also showed T2DM to be a significant predictor
of adverse outcomes after PCI compared to NDM. Death
Table 4 Results for the short-term analysis
Analyzed Outcomes No of studies analyzed Total no o of patients (n) OR (Odd ratio with 95% CI) P value I2 (%)
MACEs 2 4163 1.63 (1.17, 2.27) 0.004 0
Death 3 17,015 1.17 (1.40, 2.10) <0.00001 5
MI 2 4163 1.82 (1.08, 3.06) 0.02 0
Abbreviations: MACEs major adverse cardiac effects, MI myocardial infarction
Fig. 3 Long term adverse clinical outcomes observed between non-insulin treated T2DM and non-T2DM (part 1)
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in these patients with T2DM was reported as 2.1% com-
pared to those patients without T2DM with only 0.9%.
TVR was also higher in the T2DM group compared to
the NDM group (17.9% versus 12.8%). This PRESTO
Trial showed that compared to NDM, patients with
T2DM had an advanced age, were mostly female pa-
tients and the majority had a history of heart failure and
lower ejection fraction. These patients with T2DM were
mainly overweight and obese, and had a high rate of co-
morbidities [1].
The SORT OUT IV Trial also showed T2DM to be
associated with a significantly higher rate of MACEs
following PCI (13% in DM versus 6.4% in NDM). How-
ever, this result included patients with both ITDM and
Fig. 4 Long term adverse clinical outcomes observed between non-insulin treated T2DM and non-T2DM (part 2)
Fig. 5 Long term Target Vessel Revascularization observed between non-insulin treated T2DM and non-T2DM
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NITDM [17]. This current analysis showed long term
ST to favor the NDM group without any statistical sig-
nificance. However, the study published by Jensen et al.
in 2010 showed T2DM to be associated with an in-
creased risk of definite ST compared to NDM after PCI.
But their result included patients with both ITDM and
NITDM [18] whereas this current analysis only involved
diabetic patients without insulin therapy.
This current study only analyzed patients with
NITDM. However, several other studies compared
patients with ITDM and NITDM have shown the former
to be associated with even worse adverse outcomes after
PCI. For example, results from the FREEDOM Trial
showed that in patients with diabetes and multi-vessel
coronary artery disease, MACEs were higher in patients
treated with insulin compared to patients without insu-
lin therapy [2]. The study published by Jain et al. also
showed patients with ITDM to have significantly higher
MACEs, all-cause mortality, cardiac death as well as a
significantly greater rate of target vessel failure
Table 5 Results for the long-term analysis
Analyzed Outcomes No of studies analyzed Total no of patients (n) OR (Odd ratio with 95% CI) P value I2 (%)
MACEs 6 21,465 1.25 (1.12, 1.40) 0.0001 0
Death 8 37,756 1.32 (1.19, 1.47) <0.00001 33
MI 7 31,964 1.03 (0.89, 1.21) 0.67 17
TLR 6 30,388 1.32 (1.10, 1.59) 0.003 62
TVR 4 14,320 1.36 (1.18, 1.56) <0.0001 32
ST 9 36,900 1.13 (0.91, 1.40) 0.28 17
Abbreviations: MACEs major adverse cardiac effects, MI myocardial infarction, TLR target lesion revascularization, TVR target vessel revascularization, ST stent thrombosis
Fig. 6 Long term adverse clinical outcomes observed between non-insulin treated T2DM and non-T2DM using only randomized patients (part 1)
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compared to those diabetic patients not on insulin ther-
apy after PCI [15]. Their study also showed no signifi-
cant difference in definite and probable ST between
ITDM and NITDM. Moreover, Bundhun et al. recently
confirmed that insulin therapy was associated with sig-
nificantly higher adverse clinical outcomes compared to
NITDM whether during a short or long term follow up
period [19]. Their analysis showed results with very low
heterogeneity whereby mortality, MACEs, and revascu-
larization were significantly higher in the ITDM group
compared to the NITDM group. However, other studies
suggested factors such as female gender, insulin resist-
ance, coronary plaque vulnerability and post challenge
hyperglycemia to be responsible for these adverse clin-
ical outcomes following PCI [20–23]. However, this
current study mainly focused on NITDM and NDM.
No significant difference in ST was observed between
NITDM and NDM even if the percentage of ST among
NITDM was higher. It should be noted that NITDM
could be at an earlier stage of disease without severely
being affected by diabetic complications. However, Ford
et al. also showed a significantly improved trend in
cardiovascular diseases among a population of United
States between the years 1999 to 2000 and the years
2009 to 2010 respectively [24]. 7,751 patients from the
National Health and Nutrition Examination Survey were
used whereby a mean 10-year prediction of coronary
heart disease was 7.2 and 6.5% during the years 1999 to
2000 and 2009 to 2010 respectively, and 9.2 and 8.7% for
cardiovascular diseases during the same time period
respectively. In addition, Gregg et al. [25] also showed a
decline in the rate of complications due to T2DM be-
tween the years 1990 to 2010 which could be another
reason due to which, ST did not differ significantly be-
tween NITDM and NDM in this current analysis.
This study is new in several ways. First of all, it is the
first meta-analysis systematically comparing the adverse
clinical outcomes between NITDM and NDM patients
following PCI. Several studies compared T2DM with
NDM, ITDM with NITDM, but this is the first meta-
analysis comparing NITDM with NDM following PCI.
The short-term and long-term follow up periods analyzed
in this particular study have also added novelty to this
research. Moreover, a larger number of patients obtained
from randomized trials and observational studies were in-
cluded in this analysis further contributing to its novelty.
Limitations
This study also has limitations. First of all, due to the
smaller number of patients analyzed, a robust result
might not be expected. Moreover, in one study, all
cause-death was not reported. However, data for cardiac
death was considered and included in the subgroup
analyzing all-cause mortality. This might have an effect
Fig. 7 Long term adverse clinical outcomes observed between non-insulin treated T2DM and non-T2DM using only randomized patients (part 2)
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on the result of this analysis. In addition, several types
of ST were considered and analyzed altogether without
relying a particular definition. To be more clear, ST
defined according to protocol and ST defined according
to academic research consortium (ARC) were com-
bined and analyzed. This could have contributed to
another main limitation of this study. Furthermore, PCI
and anti-platelet therapy have evolved significantly
during the last 5 years with new technologies, and new
platelet inhibitors preventing ST and resulting in a
lower level of complications among patients with
T2DM. Ignoring this major consideration could have
had a major effect on the result of this study further
contributing to its limitations.
Conclusion
According to this analysis, short and long term MACEs
and mortality were significantly higher in patients with
NITDM compared to patients without diabetes following
PCI. Revascularization also significantly favored patients
without T2DM. However, stent thrombosis was not
significantly different.
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